Grading and Management of Prostatomegaly

Grading System for Prostatomegaly

The American Urological Association recommends grading prostatomegaly primarily by prostate volume measured via transrectal ultrasound (TRUS), with Grade 1 defined as prostate volume >30cc but <50cc, Grade 2 as 50-80cc, and Grade 3 as >80cc 1, 2

The International Prostate Symptom Score (IPSS) should be used to quantify symptom burden, independent of prostate size, with mild symptoms defined as IPSS 0-7 points, moderate symptoms as IPSS 8-19 points, and severe symptoms as IPSS 20-35 points 1, 3

For Grade 1 prostatomegaly with bothersome lower urinary tract symptoms (LUTS), alpha-blockers should be offered as first-line monotherapy, providing 4-7 point IPSS improvement within 2-4 weeks 1, 4
Combination therapy with an alpha-blocker plus a 5-alpha-reductase inhibitor should be initiated for Grade 2 prostatomegaly, reducing BPH progression risk by 67% compared to 39% for alpha-blockers alone 1, 2, 5
Patients with Grade 3 prostatomegaly should be started on combination therapy and referred to urology for surgical consultation, as medical therapy alone has limited efficacy in very large glands 5

The American Urological Association recommends repeat IPSS to quantify symptom improvement, post-void residual (PVR) measurement, uroflowmetry if available, and assessment of medication tolerability and side effects at initial assessment (4-12 weeks) 5, 4
Annual IPSS reassessment, digital rectal examination, PSA testing (remembering to double value if on 5-ARI), and monitoring for disease progression or treatment failure are recommended for long-term monitoring 1, 2, 5

In elderly patients with severe BPH and bladder outlet obstruction, the risk of acute urinary retention increases dramatically, warranting earlier urologic referral 5
The American Academy of Ophthalmology recommends that all patients on alpha-blockers must inform their ophthalmologist before cataract surgery due to intraoperative floppy iris syndrome (IFIS) risk 4, 6

The American Urological Association recommends that prostate volume >30cc indicates consideration for 5-alpha reductase inhibitor therapy, either as monotherapy or in combination with an alpha-blocker, to prevent disease progression 7

Open prostatectomy is typically performed for prostate volumes >80-100cc, as recommended by the European Association of Urology 8
Transurethral resection of the prostate (TURP) remains the benchmark surgical therapy for smaller volumes, according to the American Urological Association 9